Last reviewed · How we verify
AC regimen
AC regimen is a chemotherapy combination of doxorubicin (Adriamycin) and cyclophosphamide that damages cancer cell DNA to inhibit tumor growth.
AC regimen is a chemotherapy combination of doxorubicin (Adriamycin) and cyclophosphamide that damages cancer cell DNA to inhibit tumor growth. Used for Breast cancer (early-stage and metastatic), Lymphomas, Sarcomas.
At a glance
| Generic name | AC regimen |
|---|---|
| Sponsor | UNICANCER |
| Drug class | Chemotherapy combination (anthracycline + alkylating agent) |
| Target | DNA (topoisomerase II and DNA alkylation) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Doxorubicin is a topoisomerase II inhibitor and intercalating agent that disrupts DNA replication and transcription, while cyclophosphamide is an alkylating agent that cross-links DNA strands. Together, these agents work synergistically to induce apoptosis in rapidly dividing cancer cells. AC is typically used as neoadjuvant or adjuvant therapy in solid tumors.
Approved indications
- Breast cancer (early-stage and metastatic)
- Lymphomas
- Sarcomas
- Other solid tumors (as part of combination regimens)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity (doxorubicin-related)
- Infertility/amenorrhea
- Secondary malignancy
Key clinical trials
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Combined Effects of Niel Asher Technique and Scapular Clock Exercises in Adhesive Capsulitis (NA)
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (PHASE2)
- Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer (NA)
- Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent (PHASE2)
- Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer (PHASE2)
- Stereotactic Radiotherapy Treatment for Treatment-resistant Depression (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |